Literature DB >> 19171562

Should NICE's threshold range for cost per QALY be raised? No.

James Raftery1.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19171562     DOI： 10.1136/bmj.b185

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  NICE wobbles.

Authors:  Alan Maynard; Karen Bloor
Journal:  J R Soc Med       Date:  2009-06       Impact factor: 5.344

2.  Cost-effectiveness acceptability curves revisited.

Authors:  Maiwenn J Al
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

3.  How much should the NHS pay for a QALY?

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

Review 4.  Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases.

Authors:  Sanjib Saha; Ulf-G Gerdtham; Pia Johansson
Journal:  Int J Environ Res Public Health       Date:  2010-08-09       Impact factor: 3.390

Review 5.  Cost-effectiveness of conservative treatments for neck pain: a systematic review on economic evaluations.

Authors:  Maurice T Driessen; Chung-Wei C Lin; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2012-03-25       Impact factor: 3.134

Review 6.  Cost-effectiveness of general practice care for low back pain: a systematic review.

Authors:  Chung-Wei Christine Lin; Marion Haas; Chris G Maher; Luciana A C Machado; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2011-01-04       Impact factor: 3.134

7.  Screening of healthcare workers for tuberculosis: development and validation of a new health economic model to inform practice.

Authors:  Merve Nazli Eralp; Stefan Scholtes; Geraldine Martell; Robert Winter; Andrew Robert Exley
Journal:  BMJ Open       Date:  2012-03-01       Impact factor: 2.692

8.  How much might a society spend on life-saving interventions at different ages while remaining cost-effective? A case study in a country with detailed data.

Authors:  Giorgi Kvizhinadze; Nick Wilson; Nisha Nair; Melissa McLeod; Tony Blakely
Journal:  Popul Health Metr       Date:  2015-07-08

9.  Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population.

Authors:  Tatiana Dilla; Luís Lizan; Silvia Paz; Pilar Garrido; Cristina Avendaño; Juan J Cruz-Hernández; Javier Espinosa; José A Sacristán
Journal:  Patient Prefer Adherence       Date:  2015-12-18       Impact factor: 2.711

10.  Why Cancer?

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2016-07       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.